Bolt Biotherapeutics, Inc.

BOLTSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1641281

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenues	$7.7M	$7.9M	$5.7M	$1.3M	$231.0K
Research and Development Expense	$57.5M	$61.5M	$73.1M	$75.7M	$40.4M
Operating Expenses	$80.7M	$84.1M	$96.0M	$94.0M	$49.4M
Operating Income (Loss)	-$73.0M	-$76.2M	-$90.3M	-$92.8M	-$49.2M
Nonoperating Income (Expense)	$9.9M	$7.0M	$2.2M	-$5.8M	-$11.5M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$63.1M	—	—	—	—
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$99.6M	$159.8M	$227.8M	$307.7M	$46.5M
Assets, Current	$50.8M	$105.7M	$172.7M	$189.2M	$25.4M
Cash and Cash Equivalents, at Carrying Value	$7.2M	$10.8M	$9.2M	$27.4M	$5.5M
Liabilities	$42.4M	$47.0M	$56.3M	$57.6M	$46.2M
Liabilities, Current	$15.9M	$20.5M	$23.1M	$21.3M	$11.3M
Accounts Payable, Current	$1.5M	$3.0M	$3.6M	$3.6M	$1.6M
Stockholders' Equity Attributable to Parent	$112.7M	$171.5M	$250.1M	-$104.9M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$61.3M	-$69.5M	-$76.5M	-$57.1M	-$47.3M
Net Cash Provided by (Used in) Investing Activities	$57.6M	$71.0M	$57.9M	-$232.2M	-$20.6M
Net Cash Provided by (Used in) Financing Activities	$108.0K	$253.0K	$503.0K	$311.1M	$39.6M
Payments to Acquire Property, Plant, and Equipment	$41.0K	$206.0K	$2.0M	$2.3M	$3.3M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)